EU CHMP approves change to authorisation for Cervarix vaccine in prevention of premalignant ano-genital lesions (cervical, vulvar, vaginal and anal) and cervical and anal cancers- GlaxoSmithKline

The EU Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Cervarix vaccine, from GlaxoSmithKline. The indication now reads: Cervarix is a vaccine for use from the age of 9 years for the prevention of premalignant ano-genital lesions (cervical, vulvar, vaginal and anal) and cervical and anal cancers causally related to certain oncogenic Human Papillomavirus (HPV) types.